038070 — Seoulin Bioscience Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Seoulin Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	4,801	15,768	9,977	-2,323	3,140
Depreciation
Amortisation
Non-Cash Items	1,056	-7,437	-1,291	8,168	-982
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-4,156	-1,343	-14,059	-6,201	-8,135
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	3,684	8,918	-4,356	931	-4,611
Capital Expenditures	-943	-1,670	-707	-974	-62.4
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,652	-29,829	-1,958	28,500	6,452
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	709	-31,499	-2,665	27,526	6,389
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-402	29,008	1,077	-22,778	-7,453
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	3,955	6,475	-5,974	5,603	-5,653